Review

Regulation of Tumor and Metastasis Initiation by Chemokine Receptors

Anthony DiNatale1,2#, Maria Sofia Castelli1,3#, Bradley Nash1, Olimpia Meucci1,4 and Alessandro Fatatis1,5**

1. Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
2. Present Address: Janssen Oncology, Spring House, PA, USA.
3. Present address: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
4. Program in Immune Cell Regulation & Targeting, Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA 19107, USA
5. Program in Translational and Cellular Oncology, Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA 19107, USA.

#Equal contributions to this work.
** Corresponding author: Alessandro Fatatis, Phone: (267) 359-2630; E-mail: af39@drexel.edu.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2022.02.23; Accepted: 2022.08.10; Published: 2022.08.27

Abstract

Tumor-initiating cells (TICs) are a rare sub-population of cells within the bulk of a tumor that are major contributors to tumor initiation, metastasis, and chemoresistance. TICs have a stem-cell-like phenotype that is dictated by the expression of master regulator transcription factors, including OCT4, NANOG, and SOX2. These transcription factors are expressed via activation of multiple signaling pathways that drive cancer initiation and progression. Importantly, these same signaling pathways can be activated by select chemokine receptors. Chemokine receptors are increasingly being revealed as major drivers of the TIC phenotype, as their signaling can lead to activation of stemness-controlling transcription factors. Additionally, the cell surface expression of chemokine receptors provides a unique therapeutic target to disrupt signaling pathways that control the expression of master regulator transcription factors and the TIC phenotype. This review summarizes the master regulator transcription factors known to dictate the TIC phenotype, along with the complex signaling pathways that can mediate their expression and the chemokine receptors that are most upstream of this phenotype.

Key words: Chemokines; Initiation; Metastasis; Pluripotency

Introduction

Tumor-initiating cells (TICs) are a small population within tumors that possess stem-like properties, permitting them to initiate tumor growth as single cellular units. Their presence has been confirmed in many cancer types, including prostate, breast, colon, ovarian, and melanoma, among others [1-5]. Solid tumors can be treated with local modalities like surgery and radiation paired with systemic therapies, but the risk of distant dissemination - or metastasis - remains a major concern. Patients with metastatic lesions may achieve a temporary decrease in tumor burden with systemic treatment, but drug resistance will eventually emerge and ultimately lead to patient death [6]. As a result, most cancer deaths are not directly caused by the primary tumor, but rather are due to metastatic disease [7]. Metastasis-initiating cells (MICs) develop secondary lesions in target organs. MICs can withstand the shear forces existing in the blood vessels of the systemic circulation and disseminate to secondary sites, where they successfully colonize new tissue microenvironments and grow into metastases. Therefore, in this review we use MICs to broadly indicate cells that retain the TIC phenotype and exhibit additional properties that increase their malignancy and the potential for a lethal clinical outcome.

Tumor recurrence is a consequence of incomplete eradication of cancer cells and leads to the regrowth of existing lesions and the development of new ones. MICs have also been associated with drug resistance and are therefore well positioned to survive...
and repopulate the tumors after the ablation of most of the drug-sensitive cells by systemic therapies. In addition, clinical studies reveal that aggressive malignancies can be identified by gene expression profiles associated with stem cell pathways, and these same genes are associated with poor response to therapy for a wide range of tumors [8].

MICs have features that distinguish them from differentiated, non-stem-like cancer cells. They divide in an asymmetric fashion, giving rise to one MIC and one differentiated cell. A differentiated cell is only further capable of producing differentiated progeny harboring a higher proliferative rate and thus are responsible for constituting the majority of tumor cells. The daughter MIC then undergoes the same process of asymmetric division, generating one differentiated daughter cell and another MIC, resulting in self-renewal and maintenance of a steady-state population of MICs within the bulk tumor population [9]. Label-retaining studies provide evidence for asymmetric division as a way to self-renewal. When cellular DNA is labeled, the label is normally diluted as cells symmetrically divide, until the label can no longer be detected. In asymmetric division, the labeled DNA of MICs is retained by the MIC progeny and in gastrointestinal cancers, bromodeoxyuridine DNA labeling was elegantly used to identify label-retaining cells exhibiting a TIC phenotype [10]. MICs also have slow proliferation rates, which partially explains their resistance to anti-proliferative therapies including chemotherapies and radiotherapies [11]. These cells concurrently exploit other mechanisms of treatment resistance, including high expression of multidrug resistance proteins and enhanced cell signaling to protect against DNA damage-induced cell death [12], which underscores their involvement in tumor relapse. While treatment with first-line chemotherapy will eliminate most susceptible non-stem-like cancer cells, MICs will ultimately survive. These cells can then undergo genetic alterations, expand, and differentiate, leading to the development of metastatic lesions that result in patient death [13].

MICs are difficult to fully identify and characterize due to their low abundance. The surface receptor CD44 has been established as a stemness marker across various cancer types [14]. Another stemness marker for multiple cancer types is CD133, for which an important role has been proposed in pancreatic cancer [15] and in prostate cancer [16]. A greater understanding of the surface receptors expressed by MICs will provide not only opportunities for their isolation and characterization but will also help identifying novel therapeutic targets.

Cancer cell stemness is regulated by several pluripotency-associated transcription factors, but it is not fully known how the expression of these genes is regulated in MICs. Increasing evidence suggests this is mediated by a complex network of cell signaling pathways that differs by cancer type. Recent studies suggest that these pathways may be regulated by signaling via various chemokine/chemokine receptor pairs on MICs, which may provide a novel strategy to target the establishment and maintenance of the TIC phenotype.

Here, we describe some of the signaling pathways reportedly involved in the transcriptional regulation of pluripotency master regulators in MICs. We then review the chemokine receptors found to regulate the expression of pluripotency-associated transcription factors and discuss the tumor models in which their role in this process has been reported.

**Pluripotency master regulator transcription factors**

The TIC phenotype is regulated by several pluripotency-associated transcription factors, including octamer binding transcription factor 4 (OCT4), sex determining region Y-related high mobility group box 2 (SOX2) and nanog homeobox (NANOG). Upregulation of these genes helps cancer cells acquire stemness properties, and thus, they are considered critical regulators of self-renewal and pluripotency that mediate tumor proliferation and differentiation [17-19].

**OCT4a**

OCT4 (also known as OCT3) is a transcription factor encoded by the Pou5f1 gene. In humans, this gene can generate three isoforms by alternative splicing, known as OCT4a, OCT4b and OCT4b1 [20]. OCT4a, normally referred to as OCT4, has been established as a marker for human pluripotent embryonic stem cells. OCT4 is a transcription factor that maintains the pluripotent state during embryonic development, and its loss leads to stem cell differentiation [20,21]. The other isoforms, OCT4b and OCT4b1, may play a role in the biologic response of cells to stress [22,23]. Accumulating evidence suggests that OCT4 helps maintain stemness features in cancer, thus playing a major role in self-renewal, cell survival, metastasis and drug resistance in MICs through the regulation of its target genes [17]. OCT4 is overexpressed in MICs in various cancers and its high expression correlates with poor clinical outcomes [24]. OCT4 also forms heterodimers with other transcription factors like SOX2, which can occur via their unique interactions with DNA. The OCT4 POU domain interacts with the major groove of the DNA,
whereas a SOX2 high-mobility group (HMG) domain interacts with the minor groove of DNA [25], allowing OCT4 and SOX2 to dimerize with each other. This interaction drives the transcription of their target genes, which also includes SOX2, OCT4, and NANOG [26].

**SOX2**

SOX2 is a transcription factor in the Sry-related HMG box (SOX) family of proteins, which bind to specific DNA sequences via a highly conserved HMG domain. SOX2 regulates the pluripotency and self-renewal of stem cells during embryonic development and adult tissue regeneration [27]. It is also involved in tumorigenesis in a wide range of cancers, including those of the breast, prostate, brain, lung, kidney, and skin. SOX2 regulates its target genes to promote cancer cell growth, invasion, migration, metastasis, and chemoresistance [28]. Overexpression of SOX2 correlates with a stem-like phenotype in cancer and has been implicated in poor survival rates of cancer patients [28].

**NANOG**

NANOG is a transcription factor with a DNA-binding homeodomain that helps maintain pluripotency in embryonic stem cells and is downregulated upon differentiation [29]. As mentioned, NANOG expression is regulated by the OCT4/SOX2 complex, but NANOG can also be maintained without OCT4 involvement through activation by FoxD3 [30]. Like OCT4 and SOX2, NANOG can promote cell survival, anti-apoptotic signaling, migration, invasion, and chemoresistance, and is overexpressed in various cancers, including breast, ovarian, melanoma, and others [31].

Although there is a wide understanding of the role of the master regulators OCT4, SOX2, and NANOG in embryonic stem cells, it is crucial that we establish the same knowledge in MICs. While it is now evident that high expression of these pluripotency-associated transcription factors indicates a poor prognosis across cancer types, the mechanistic underpinning of this observation remains limited. By elucidating the signaling pathways that are hijacked by MICs to activate OCT4, SOX2, and NANOG, we will expand the number of targetable options for treating or controlling metastatic disease.

**Signaling pathways that activate the pluripotency master regulator transcription factors**

Like the master regulators OCT4, SOX2, and NANOG, multiple molecular signaling pathways that regulate cellular pluripotency are also dysregulated in cancer (Figure 1).

**PI3K/AKT pathway**

The phosphatidylinositol-3-kinase (PI3K)/AKT pathway regulates many physiologic cellular processes, such as cell growth, proliferation, and survival. As these processes are also crucial for tumorigenesis, the PI3K/AKT pathway is often affected by genomic aberrations in cancer, thus contributing to tumor initiation and progression [32].

The PI3K/AKT pathway can regulate the expression of several pluripotency-associated transcription factors. Several studies have suggested that the PI3K/AKT pathway cooperatively interacts with SOX2 in cancer. Specifically, AKT kinase activity drives SOX2 nuclear localization and stabilization, and SOX2 supports PIK3CA gene expression that leads to further AKT activation [33]. In breast cancer, SOX2 appears to act as a functional downstream AKT target, with a direct physical interaction between the two proteins. AKT phosphorylation of SOX2 can modulate SOX2 nuclear entry and its action on target genes, while inhibition of AKT leads to SOX2 retention in the cytosol and promotes its degradation via the proteasome [34]. Similar studies in nasopharyngeal carcinoma and esophageal cancer show that PI3K/AKT signaling regulates SOX2 expression. AKT in nasopharyngeal carcinoma regulates the expression of the cell cycle regulator p27, which in turn modulates SOX2 expression [35], and AKT in esophageal cancer promotes overexpression of SOX2 and protects SOX2 from proteasomal degradation [36]. In prostate cancer, PI3K/AKT is a key signaling pathway that maintains the SOX2/OCT4-overexpressing TIC population in vitro and in vivo [37]. Indeed, prostate cancer MICs can upregulate SOX2 protein via TGF-α-mediated activation of the EGFR/PI3K/AKT pathway [38].

Multiple cancer types also show a reciprocal relationship between the PI3K/AKT pathway and OCT4. In embryonal carcinoma, AKT phosphorylates OCT4, which stabilizes OCT4 and facilitates its nuclear localization and interaction with SOX2 [39]. This in turn promotes the transcription of the core stemness genes OCT4 and NANOG. Consequently, the levels of phosphorylated OCT4 in these cells positively correlated with tumorigenic potential in a xenograft model and resistance to apoptosis. Phosphorylation of OCT4 by AKT also led to dissociation of OCT4 from the AKT1 promoter, which activated AKT1 transcription and promoted cell survival [39]. Similarly, AKT phosphorylation of OCT4 was associated with the proliferation of glioblastoma cancer cells in vitro, and when the authors attenuated AKT activation using the aryl
hydrocarbon receptor ligand ITE, they found reduced proliferation of glioblastoma spheroids [40]. OCT4 expression may also be regulated by nitric oxide (NO), a molecule that is upregulated in lung cancer and affects several cellular processes. In the absence of NO, OCT4 forms a molecular complex with the protein caveolin-1 that promotes its proteasomal degradation, but in the presence of NO, caveolin-1 is phosphorylated by AKT, which disrupts its complex with OCT4 and prevents OCT4 degradation in vitro [41]. In breast cancer, PD-L1 helps maintain a stemness phenotype in MICs in vitro and in a mouse xenograft model via PI3K/AKT signaling that leads to phosphorylation of OCT4 and subsequent regulation of OCT4 and NANOG expression [42]. Notably, PD-L1 knock-down inhibited the phosphorylation of AKT and OCT4, which was associated with decreased stemness and self-renewal of breast cancer with TIC phenotype both in tumorspheres in vitro and in an in vivo extreme limiting dilution assay. Finally, in lung cancer cells an activated AKT-ubiquitin proteasome degradation pathway downregulated OCT4 and NANOG as well as other TIC markers in vitro, further suggesting the PI3K/AKT pathway regulates these transcription factors [43].

**Hedgehog pathway**

The Hedgehog (Hh) pathway is essential for normal embryonic development but also regulates genes involved in various processes in cancer, including differentiation, proliferation, and carcinogenesis [44].

![Figure 1. Overview of the pathways mediating chemokine receptor-driven activation of master regulator transcription factors and the TIC phenotype.](https://www.jcancer.org)
The Hh pathway plays a role in the maintenance and function of stemness features in MICs, including tumor initiation and resistance to chemotherapy and radiotherapy [44]. The stemness phenotype induced by Hh signaling seems to be driven by transcriptional regulation of pluripotency-associated genes. In melanoma, Hh signaling increased SOX2 expression and thereby supported self-renewal and tumorigenicity, whereas SOX2 silencing or depletion blocked cell growth, sphere formation, and the ability to initiate tumors in xenograft models [45]. In pancreatic cancer, cooperation of Hh and EGFR signaling induced high-level expression of SOX2 that promoted both tumor initiation and tumor growth [46]. As before, these effects were mitigated by knock-down of Hh/EGFR cooperative genes, including Sox2, Jun, and Cxcr4. Additionally, pancreatic cells with a TIC phenotype have been reported to show high levels of Hh activity that is thought to drive stemness features. Indeed, inhibition of Hh signaling in these cells in vitro decreased their expression of OCT4 and NANOG, reduced spheroid proliferation, and induced cellular apoptosis [47]. In glioma-initiating cells (GICs), Hh signaling regulated SOX2 expression by helping Gli2 bind to the SOX2 promoter, and this pathway as well as GIC properties was mitigated by knock-down of urokinase receptor (uPAR) and cathepsin B [48]. In another study of gliomas, treatment with an inhibitor of the Hh pathway decreased expression of OCT4, SOX2, and NANOG in GICs [49], further supporting that this pathway regulates stemness. Similarly in breast cancer, Hh signaling can be enhanced via expression of tetraspanin 8 and LncRNA-Hh, which increases the expression of OCT4, SOX2, and NANOG and leads to enhanced self-renewal and oncogenicity [50,51]. Collectively, it is evident that Hh signaling regulates pluripotency genes in numerous cancer types.

**NF-κB pathway**

The nuclear factor-κB (NF-κB) family of transcription factors plays crucial roles in cell survival, proliferation, apoptosis regulation, immunity, and inflammation [52]. The NF-κB pathway controls the transcription of a large subset of genes, including central components of the immune response such as cytokines, as well as regulators of apoptosis, proliferation, and development [53]. Thus, dysregulation of this pathway has been associated with several diseases, including immune disorders and cancer [52].

Activation of the NF-κB pathway has been associated with tumor initiation and progression through supporting processes such as cell survival, invasion, metastasis, angiogenesis, and apoptosis resistance. NF-κB activation is enhanced in MICs from various tumor types, including glioblastoma, prostate, breast, and ovarian [54]. In lung cancer, inhibiting NF-κB signaling using an IκB kinase inhibitor mitigated stemness features [55]. This was mediated by the reduced transcription of NF-κB target genes, which include the pluripotency genes OCT4, SOX2, and NANOG as well as genes involved in EMT and resistance to apoptosis. Similarly in breast cancer, the NF-κB pathway regulates the expression of OCT4, SOX2, and NANOG via upregulation of components of the NF-κB signaling pathway, including NIK [56,57]. As expected, breast tumor growth was delayed by inhibiting NF-κB in a transgenic mouse model as well as knocking down NIK in breast cancer cells used for mouse xenograft studies. In castration-resistant prostate cancer cells, this pathway helps regulate the expression of OCT4, SOX2, and NANOG by activating a p65-mediated feed forward circuit that leads to the phosphorylation of IκBα [58]. This pathway was also observed in a mouse xenograft model as well as human prostate tumors, further suggesting the importance of NF-κB signaling to stemness phenotypes. In ovarian cancer cells, cisplatin treatment enriched for a population with stemness features and induced NF-κB translocation to the nucleus, most prominently in cells with high OCT4 expression. Enhanced nuclear co-localization of NF-κB with OCT4 led to the increased expression of OCT4, SOX2, and NANOG and induced a TIC phenotype in these cells [59]. The NF-κB pathway also regulates OCT4 expression in colorectal cancer via the signaling of pro-inflammatory cytokines interleukin-6 (IL-6) and TNFα, which induces stem-like behavior [60].

**JAK/STAT pathway**

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is involved in many important biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation. The main components of this pathway are a tyrosine kinase-related receptor, the tyrosine kinase JAK, and the transcription factor STAT.

Aberrant JAK/STAT activation has been detected in many tumors, including by JAK2 mutations that lead to STAT3 activation, and constitutive STAT3 activation independent of JAK2 mutations [61]. JAK/STAT signaling plays a major role in many aspects of tumorigenesis, including proliferation, apoptosis, angiogenesis, and metastasis [62]. Furthermore, JAK/STAT signaling helps
establish and maintain the TIC phenotype in different cancer types, including breast cancer, non-small-cell lung cancer, endometrial cancer, colorectal cancer, and gliomas [61]. For example, in HER2-overexpressing ER-positive human breast tumors, Wnt/β-catenin-independent. Wnt signaling engages with carcinogenesis in various malignancies, including gastrointestinal cancers, leukemia, melanoma, and breast cancer. Wnt signaling contributes to the development of metastasis and the regulation of stemness features and tumor initiation [70]. In MICs, the Wnt pathway is reported to upregulate proteins that inhibit differentiation, counteract apoptosis, and promote cell migration and invasion [61]. In a non-small cell lung cancer cell line, Wnt/β-catenin signaling can control the transcript and protein levels of OCT4, and knock-down of β-catenin reduced OCT4 expression and mitigated a variety of stem-like properties in vitro [71]. Additionally in non-small cell lung cancer, FOXC1 induces TIC properties by promoting β-catenin expression. In this study, β-catenin overexpression expanded the TIC sub-population, promoted tumorsphere formation, induced therapy resistance, and upregulated the levels of SOX2, OCT4, NANOG, and ATP-binding cassette transporter G2 (ABCG2), whereas β-catenin knock-down resulted in the opposite effects [72]. In colorectal cancer, formation of a β-catenin/TCF4:c-Jun complex is a key nuclear mediator for NANOG activity, and this complex controls a sub-population of cells associated with the high expression of Wnt-target genes [73]. Indeed, resected mouse xenografts from this study showed that NANOG-GFP expressing cells had high levels of nuclear β-catenin, and these cells formed colony units in vivo. In gastric cancer cells, infection with Helicobacter pylori containing the CagA bacterial oncprotein activated Wnt/β-catenin signaling via Akt and/or c-met mediated phosphorylation of β-catenin, which upregulated NANOG and OCT4 and increased stemness features [74]. The Wnt pathway is associated with stemness and radiotherapy resistance in pancreatic carcinoma MICs, as HMGB1:TLR2/Wnt/β-catenin signaling regulated the expression of OCT4, SOX2, and NANOG [75]. Interestingly, HMGB1 reduced stemness features upon binding an alternative receptor, TLR4, suggesting a balance of TLR2/TLR4 expression can regulate pancreatic cancer stemness. Additionally, in many cancer types OCT4 may activate Wnt/β-catenin signaling, suggesting a reciprocal regulation between these proteins to promote stemness [76].

**Wnt pathway**

The Wnt pathway is a highly complex, evolutionarily conserved signaling pathway that includes many ligands and receptors [69]. Signaling through this pathway can be distinguished as canonical, which is mediated by the transcriptional regulator β-catenin, or non-canonical, which is β-catenin-independent. Wnt signaling is engaged during development and has also been associated with carcinogenesis in various malignancies, including gastrointestinal cancers, leukemia, melanoma, and breast cancer. Wnt signaling contributes to the development of metastasis and the regulation of stemness features and tumor initiation [70]. In MICs, the Wnt pathway is reported to upregulate proteins that inhibit differentiation, counteract apoptosis, and promote cell migration and invasion [61]. In a non-small cell lung cancer cell line, Wnt/β-catenin signaling can control the transcript and protein levels of OCT4, and knock-down of β-catenin reduced OCT4 expression and mitigated a variety of stem-like properties in vitro [71]. Additionally in non-small cell lung cancer, FOXC1 induces TIC properties by promoting β-catenin expression. In this study, β-catenin overexpression expanded the TIC sub-population, promoted tumorsphere formation, induced therapy resistance, and upregulated the levels of SOX2, OCT4, NANOG, and ATP-binding cassette transporter G2 (ABCG2), whereas β-catenin knock-down resulted in the opposite effects [72]. In colorectal cancer, formation of a β-catenin/TCF4:c-Jun complex is a key nuclear mediator for NANOG activity, and this complex controls a sub-population of cells associated with the high expression of Wnt-target genes [73]. Indeed, resected mouse xenografts from this study showed that NANOG-GFP expressing cells had high levels of nuclear β-catenin, and these cells formed colony units in vivo. In gastric cancer cells, infection with Helicobacter pylori containing the CagA bacterial oncprotein activated Wnt/β-catenin signaling via Akt and/or c-met mediated phosphorylation of β-catenin, which upregulated NANOG and OCT4 and increased stemness features [74]. The Wnt pathway is associated with stemness and radiotherapy resistance in pancreatic carcinoma MICs, as HMGB1:TLR2/Wnt/β-catenin signaling regulated the expression of OCT4, SOX2, and NANOG [75]. Interestingly, HMGB1 reduced stemness features upon binding an alternative receptor, TLR4, suggesting a balance of TLR2/TLR4 expression can regulate pancreatic cancer stemness. Additionally, in many cancer types OCT4 may activate Wnt/β-catenin signaling, suggesting a reciprocal regulation between these proteins to promote stemness [76].

**Notch pathway**

The Notch pathway is an evolutionarily conserved signaling mechanism involved in the development of various organs during embryogenesis and in adult tissue homeostasis [77]. The pathway is also involved in various malignancies and can act as an oncogene or as a tumor suppressor depending on factors such as signal strength, timing, cell type, and
Numerous studies have shown that activation of Notch promotes cell survival, self-renewal, and metastasis [61]. In colon cancer, all Notch receptors, but particularly Notch2, regulate stemness in MICs. Notch2 had the highest expression in MICs compared with other Notch receptors, and suppression of this receptor decreased expression of OCT4 and SOX2 [79]. Additionally, Notch signaling is associated with SOX2 transcription, which seems to be reciprocal in some cancer types. For instance, hypoxia in ovarian cancer cells increases SOX2 promoter activity through Notch1 activation, which leads these cells to acquire stemness features including chemoresistance, tumorsphere formation, and the expression of specific cell-surface markers [80]. Malignant glioma can feature a Notch1-SOX9-SOX2 positive-feedback loop that controls glioma stem cell invasion along white matter tracts. In this case, Jagged1-mediated Notch signaling activates SOX9, which then promotes SOX2 transcription [81]. Furthermore, glioblastoma with TIC phenotype show upregulation of Notch1 signaling proteins NICD and Hes-1, and knock-down of Notch1 in these cells diminishes their tumorsphere formation ability, self-renewal, chemoresistance, and expression of OCT4, SOX2, and NANOG [82]. Notch1 also appears to critically regulate stemness in head and neck squamous cell carcinoma (HNSCC) cells, as constitutive activation of NICD in HNSCC cells promotes self-renewal by enhancing tumorsphere formation and upregulating stemness markers such as OCT4, SOX2, and CD44. In contrast, Notch1 knock-down in primary HNSCC cells attenuated their TIC traits, sensitized them to chemotherapy and inhibited tumor formation in a mouse xenograft model. Notably, Notch1 acted upstream of canonical Wnt signaling in HNSCC cells [83]. Finally, Notch1 is involved in the regulation of stemness in thyroid cancer cells [84]. This study found that Notch1 knock-down led to downregulation of proteins related to stemness and EMT markers, including Notch1, SOX2, OCT4, and NANOG, and decreased cell viability and migration [84].

In summary, both the TIC phenotype and the expression of OCT4, SOX2, and NANOG are dictated by a collective of signaling pathways, all of which have been previously established as pro-tumorigenic. While this review highlights the progress in revealing the connection between these signaling pathways to the TIC phenotype, further studies are required to fully understand the complex mechanism in which these signaling pathways lead to the expression of pluripotency-associated transcription factors. Developing a full understanding of how components of these signaling pathways establish the TIC phenotype will provide a unique opportunity to discover promising means of targeting MICs.

Chemokines and chemokine receptors that regulate pluripotency genes

Chemokines are small cytokines that direct immune cells to migrate to specific organs and regulate inflammation and immunity. These proteins are also involved in many other biological processes, including cell proliferation, survival, and differentiation. Chemokines exert their effects by binding to chemokine receptors, and are divided into four subfamilies (CC, CXC, CX3C, and XC) based on the configuration of the two cysteines closest to the N terminus. Chemokine receptors are also divided into four groups based on the subfamilies of chemokines they bind [85]. Conventional chemokine receptors are seven-transmembrane G protein-coupled receptors (GPCRs) that typically transduce signals through Gαiq pathways, although some receptors couple to Gαq family members [85,86]. Chemokines are well-documented contributors to tumor progression as they recruit leukocytes such as regulatory T cells (Tregs), and promote angiogenesis, tumor growth and proliferation, and metastasis. As a result, many chemokine receptor inhibitors have been designed as therapeutics for cancer [87]. Furthermore, numerous studies suggest that chemokine/chemokine receptor pairs regulate the TIC phenotype. This is consistent with the fact that chemokines signal through a complex network of pathways, many of which appear to play crucial roles in tumor initiation. In turn, several chemokine receptors are upregulated during tumorsphere formation, and several of these receptors are confirmed to regulate stemness features [88]. Some chemokine receptors have been described as MIC markers, including CXCR1/2 and CXCR4 [89] (please see also Table 1).

CXCR subfamily

CXCR1/2

The chemokine receptors CXCR1 and CXCR2 share considerable structural similarity, as 78% of their amino acid sequences are identical [90]. Both receptors can couple to the same Gαi and Gαq GTP binding proteins and are present in the same cells, but they have unique ligand specificity. While CXCR1 only binds to two ligands (CXCL6 and CXCL8), CXCR2 is less selective, and its known ligands include CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 [86]. Both CXCR1 and CXCR2 are expressed on granulocytes, monocytes, mast cells, and NK cells, and can also be expressed on cancer cells [91,92].
Table 1. Chemokine receptors and cellular signaling pathways they activate that have been found associated with MICs.

| Disease                      | CXCL1/2                                                                 | CXCR3                                                                 | CXCR4                                                                 | CXCR7                                                                 | CX3CR1                                                                 | CCR4                                                                 | CCR7                                                                 |
|------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Breast cancer                | CXCL8> P13K/AKT, PKC, ERK1/2 [97]                                       | CXCL10/CXCL11-CXCR3B> STAT3, ERK1/2, CREB, Notch1 [114]               | CXCL12> NF-kB-p65 [129]                                             | CXCL12> NF-kB-p65 [129, 131]                                         | CX3CL1> Src/FAK [139], ERK1/2 [140]                                   | CCL17/CCL22-mediated [150]                                          | CCL21> P13K/AKT, GSK3B, Snail [159]                                  |
| Colorectal cancer            | CXCL8> p21 [102], Snail>E3/E4 E-boxes>CXCL8 [103], P13K/AKT, Notch, Wnt, NF-kB [103] | CXCL10-CXCR3A> ERK1/2 [112]                                        | CXCL12> P13K/AKT, ERK1/2, NF-kB [119]                               |                                                                      |                                                                       |                                                                      |                                                                       |
| Esophageal cancer            |                                                                      |                                                                      |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |
| Gastric cancer               |                                                                       |                                                                      |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |
| Glioblastoma                 | CXCL8> ERK1/2, P13K/AKT [105]                                         |                                                                      |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |
| Hepatocellular carcinoma     | CXCL8-mediated [98], CXCL3> ERK1/2, ETS1 [108]                         | CXCL11> ERK1/2 [115]                                               |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |
| Lung cancer                  | IL-8 mediated [96,100]> ERK1/2 and P13K/AKT [101]                      |                                                                       | CXCL12> P13K/AKT, mTOR, STAT3 [121]                                 |                                                                       | CX3CL1> Src/FAK [137]                                                |                                                                      |                                                                       |
| Oral squamous cell carcinoma |                                                                         |                                                                      |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |
| Ovarian cancer               |                                                                         |                                                                      |                                                                       |                                                                       |                                                                       | CCL21> JAK2/STAT3 [160]                                               |                                                                       |
| Pancreatic cancer            | CXCL8-mediated [96]                                                    |                                                                      |                                                                       |                                                                       |                                                                       |                                                                       |                                                                       |
| Prostate cancer              |                                                                         |                                                                      |                                                                       |                                                                       |                                                                       | CCL21> ERK1/2, NF-kB, p65 [156]                                       |                                                                       |
| Renal cell carcinoma         | CXCL6/CXCL7-mediated [110]                                            |                                                                      | CXCL12-mediated [118]                                               |                                                                       |                                                                       |                                                                      |                                                                       |
| Thyroid cancer               | CXCL8-mediated [105]                                                  |                                                                      |                                                                       |                                                                       |                                                                       |                                                                      |                                                                       |

The chemokine ligands for CXCR1/2 are expressed and secreted by different cancer cell types, and these ligands stimulate proliferation and migration by acting in an autocrine fashion [92]. The most potent ligand for both CXCR1 and CXCR2 is CXCL8, also known as interleukin-8 (IL-8) [90,93]. IL-8 is a pro-inflammatory CXC chemokine produced by various cell types that recruits neutrophils to sites of infection or tissue injury [92]. IL-8-receptor binding induces a multitude of pathways. Of great importance are the activation of PI3K and phospholipase C, which promote the activation of AKT, PKC, calcium mobilization, and/or MAPK signaling cascades. These pathways enhance cell survival and migration in both neutrophils and cancer cells [91]. IL-8 signaling also promotes the nuclear translocation of STAT3 and β-catenin and activates RhoGTPases and tyrosine kinases such as Src and focal adhesion kinase (FAK) that regulate the cytoskeleton and mediate cell motility and invasion [94].

IL-8 and its receptors are expressed by cancer cells as well as infiltrating immune cells, and IL-8 signaling in both cell types is involved in angiogenesis, proliferation, survival, migration, and chemotherapeutic resistance [94]. Furthermore, the IL-8-CXCR1/2 axis regulates stemness features in...
MICs of various cancer types, including lung cancer [95], pancreatic cancer [96], breast cancer [97], and hepatocellular carcinoma [98]. Breast cancer MICs express CXCR1 and CXCR2, and both receptors help to establish and maintain a stemness phenotype and induce EMT, thus contributing to metastasis [99]. As expected, the IL-8-CXCR1/2 axis also regulates the expression of pluripotency-associated genes. In small-cell lung cancer, IL-8 transcript expression and protein secretion is increased in MICs, and this chemokine acts in an autocrine fashion to induce stemness features including self-renewal, migration, tumorsphere formation, and the expression of stemness related genes [100]. Knock-down of IL-8 in these MICs led to a decrease in OCT4 and NANOG expression as well as an inhibition of tumor growth in a mouse xenograft model, while treatment with exogenous recombinant human IL-8 upregulated SOX2 and NANOG in vitro [100]. CXCR1/2 and their ligands are both expressed by lung cancer cells, and receptor inhibition with an antagonist decreased migration and enhanced apoptosis in vitro and suppressed tumour growth, metastasis, and angiogenesis in a mouse xenograft model [101]. Resected lung cancer xenografts from this study provided information on how the antagonist repressed important molecular pathways, including ERK1/2 and AKT pathways as well as the expression of NF-κB p65 and vascular endothelial growth factor (VEGF).

In colorectal cancer, both CXCR1 and IL-8 are overexpressed in patients’ diseased colon tissue specimens, and their expression, in conjunction with the stemness marker aldehyde dehydrogenase 1 (ALDH1), was correlated with poor survival [102]. This study also noted that knocking down CXCL8 or CXCR1 from primary colon cancer isolates decreased their proliferation and angiogenesis in vitro and in a secondary xenograft model, which was associated with the dysregulation of several cell cycle proteins. Also, in primary colorectal cancer cells/tissues the EMT activator Snail was overexpressed in stem-like cells and promoted the expression of several hundred Snail-activated genes, which notably include IL-8 [103]. Snail bound directly to the IL-8 promoter E3/E4 E-boxes to facilitate IL-8 expression, and deletion or mutagenesis of select residues in these regions mitigated IL-8 expression in vitro [103]. Snail overexpression correlated with self-renewal and chemoresistance, and these properties were reverted when IL-8 activity was blocked using a neutralizing antibody. Furthermore, both shRNA-mediated IL-8 knock-down and IL-8 neutralization decreased the expression of SOX2, NANOG, and OCT4 in MICs [103]. Notably, Snail can be expressed in primary tumors and metastases, and its expression is regulated by an integrated and complex signaling network that includes PI3K/AKT, TGF-β, Notch, Wnt and NF-κB pathways [104].

CXCR2 is also overexpressed in GICs, and IL-8 increases the self-renewal capacity of glioblastoma cells and the expression of GIC markers in vitro and enhances tumor growth and therapy resistance in vivo [105]. Specifically, IL-8 activation of CXCR2 in glioblastoma cell lines significantly increased SOX2 and NANOG expression and immunoblot analysis of tumor cell lines obtained from patient-derived xenografts (PDXs) and exposed to IL-8 showed a time-dependent increase in the expression of critical GIC-associated transcription factors, including NANOG, SOX2, and OCT4 [105].

In addition to IL-8, other chemokine ligands for CXCR1/2 can regulate stemness, although this depends on the specific ligand and cancer type. For instance, a study in thyroid cancer compared how two CXCR2 ligands, CXCL1 and IL-8, regulate stemness features. Only IL-8 was crucial for self-renewal, tumorsphere formation and tumor initiation capabilities as well as the expression of the stemness markers OCT4, SOX2, and NANOG. IL-8 expression was also correlated with lymph node metastasis [106]. In contrast, colon cancer cells treated with CXCL1 showed increased tumor-initiating properties, including tumorsphere formation and the expression of OCT4, NANOG, SOX2 and other stemness markers in vivo [107]. Another CXCR2 ligand, CXCL3, may regulate stemness features in hepatocellular carcinoma, including proliferation, self-renewal, and tumorigenesis in vitro [108]. CXCL3 was significantly overexpressed in a CD133+ sub-population within hepatocellular carcinoma, and siRNA silencing of CD133 reduced tumor weight in a mouse xenograft model and led to reduced expression of CXCL3 in vitro, demonstrating a positive correlation between the two proteins [108]. Exogenous CXCL3 treatment increased the expression of OCT4 and other stemness-related genes including EP300, Tert, and β-catenin, while CXCL3 knock-down downregulated these same genes. The authors of the study proposed that CXCL3 may regulate stemness features through the MAPK pathway by activating ERK1/2, which phosphorylates ETS1 [108]. Furthermore, high CXCR2 expression has also been reported in hepatocellular carcinoma. One study demonstrated that CXCR2 expression correlates with intrahepatic metastasis and decreased differentiation but no other factors like age and gender, AFP levels, tumor capsule, or tumor size [109]. Finally, CXCR2 signaling in renal cell carcinoma can be regulated by galectin-3 (Gal-3), which in turn regulates the stemness features of renal MICs [110].
This study showed that Gal-3 silencing via shRNA inhibited CXCL6- and CXCL7-mediated CXCRII signaling in MICs and simultaneously inhibited the expression of NANOG and SOX2, therefore suppressing the stemness phenotype of these cells. Interestingly, CXCRII overexpression restored NANOG and SOX2 expression as well as the stem-like features in Gal-3-silenced MICs. Furthermore, overexpression of Gal-3 in renal carcinoma cells promoted in vivo tumorigenicity in a mouse xenograft model [110].

**CXCR3**

CXCR3 is a chemokine receptor expressed on monocytes, T cells, NK cells, and dendritic cells (DCs), and its ligands include CXCL11, CXCL10, CXCL9, and CXCL4. The receptor plays roles in inflammation, wound healing, and immunity, and additionally in both autoimmune diseases and tumor progression [111].

CXCR3 has two major isoforms formed by alternative splicing, CXCR3A and CXCR3B. CXCR3A expression was previously implicated in metastasis, as it promotes cell migration and invasion in various cancers, including colorectal and gastric [112,113]. In contrast, CXCR3B appears to regulate stemness. In breast cancer, CXCR3B is upregulated in MICs, and its overexpression increases the number of these cells, while its silencing has the opposite effect [114]. In addition, small molecule inhibition of CXCR3 blocks breast cancer cells from colonizing the lung when injected intravenously in mice. This regulation seems to occur through CXCR3 ligand-mediated activation of STAT3, ERK1/2, CREB, and NOTCH1 pathways [114]. Furthermore, the CXCR3 ligand CXCL11 was upregulated in hepatocellular carcinoma MICs and induced the expression of stem cell-related genes, including NANOG. In this study, CXCL11 signaling through CXCR3 led hepatocellular carcinoma cells to acquire and maintain properties like self-renewal, tumorigenicity, and chemoresistance via activation of the ERK1/2 pathway, and CXCL11 knock-down reduced tumorigenicity in a mouse xenograft model [115].

**CXCR4**

CXCR4 is expressed by most hematopoietic cell types, and its main ligand is CXCL12, also known as stromal cell-derived factor 1 (SDF-1). CXCR4 plays a role not only in leukocyte recruitment, but also in crucial processes during embryogenesis, including the development of the hematopoietic, cardiovascular, and nervous systems [116]. This chemokine receptor is also involved in pathologies including human immunodeficiency virus (HIV) infection, where it acts as a HIV co-receptor, as well as cancer and immune diseases. CXCR4 activation and subsequent signal transduction regulates gene transcription, chemotaxis, cell survival, and proliferation. CXCR4 signaling pathways activated by ligand binding include PI3K-AKT-NF-κB, MEK1/2, and ERK1/2, as well as JAK/STAT signaling in a G-protein-independent manner [117] (Figure 2).

CXCR4 is overexpressed in multiple cancer types and contributes to tumor growth, invasion, migration, metastasis, relapse, and therapy resistance [117]. Furthermore, CXCR4 has been previously associated with the regulation of the TIC phenotype. In renal cell carcinoma cells, CXCR4 is preferentially expressed in cells with high expression of OCT4, SOX2, and NANOG. These CXCR4 expressing cells had increased therapy resistance, tumorsphere formation and tumor growth capabilities compared to cells that lacked CXCR4 expression, and CXCR4 knock-down by siRNA mitigated these stemness features [118]. CXCR4 is also involved in chemotherapy resistance in colorectal cancer cells. Oxaliplatin-resistant colorectal cancer cells strongly expressed CXCR4, and in vitro treatment with a CXCR4 antagonist mitigated treatment resistance and the downstream pathways involved, including PI3K/AKT and ERK1/2 intracellular signaling cascades and the NF-κB transcription factor [119]. Similarly, upregulation of the CXCL12/CXCR4 axis was reported in esophageal MICs, and this signaling axis maintained a TIC phenotype in these cells via activation of the ERK1/2 pathway [120]. This study demonstrated that CXCR4 and ERK1/2 activation enhanced esophageal cancer cell line migration and invasion in transwell and Matrigel models, which was blocked by antagonists of both proteins or CXCR4 silencing. A study in non-small cell lung cancer showed that CXCR4 expression was higher in a drug-resistant cell line compared with the parental cell line, suggesting that this chemokine receptor is involved in drug resistance [121]. The authors used fluorescence activated cell sorting (FACS) to isolate cells expressing and cells lacking CXCR4, which revealed that CXCR4 expressing cells had significantly higher levels of OCT4, SOX2, and NANOG. CXCR4 expressing cells also displayed higher self-renewal potential, drug resistance, and tumorigenic potential in a mouse xenograft model. This study also showed that CXCR4 expression was regulated by the PI3K/AKT/mTOR pathway, while the CXCR4 downstream effector STAT3 seemed to regulate stemness features [121].
Figure 2. The chemokine CXCL12 is engaged by two different receptors, CXCR4 and CXCR7. CXCR4 downstream signaling regulates gene transcription, chemotaxis, cell survival, and proliferation. The signaling pathways activated upon CXCL12 binding to CXCR4 and subsequent recruitment of G proteins include PI3K-AKT, NF-κB and MAPK, whereas the JAK/STAT signaling pathway is recruited in a G-protein-independent manner. All these pathways support malignancy and stemness features. Unlike typical GPCRs, CXCR7 is generally not coupled to G proteins. This receptor can activate MAPK effectors via β-arrestin, whereas in some cell types it can form heterodimers with CXCR4 and act as a co-receptor. Additionally, CXCR7 has been proposed to scavenge excess CXCL12 through high-affinity binding and degradation, thus modulating ligand binding to CXCR4. Created with Biorender.com.

MICs may use CXCR4 to maintain their stemness features via regulation of pluripotency-associated genes. In GICs, various studies have described upregulation of the CXCL12/CXCR4 pathway as well as CXCR4-mediated regulation of pluripotency-associated genes, proliferation, invasion, angiogenesis, and therapy resistance [122-125]. For instance, CXCR4 is essential for the self-renewal of glioblastoma GICs, since disruption of CXCL12/CXCR4 signaling and its downstream ERK and AKT pathways reduced expression of OCT4 and NANOG in vitro [123]. This was further supported by a study in human patient specimens that showed CXCR4 is co-expressed with OCT4, SOX2, and NANOG in both primary and recurrent glioblastomas [124]. Additionally, glioblastoma cells treated with a small-molecule CXCR4 inhibitor showed decreased expression of TIC markers, including SOX2 and NANOG [122]. This same inhibitor also increased apoptosis, reduced CXCR4 expression and cell migration in vitro, and impaired tumor initiation in a mouse subcutaneous xenograft model as well as a mouse model where glioblastoma cells were directly injected into the brain [122]. Furthermore, in glioblastoma the inhibition of CXCR4 and CXCL12 by a miRNA cluster blocked tumor development in mice with cancer cells implanted into the striatum and decreased the expression of OCT4 and NANOG in vitro. The authors suggested that NANOG expression was regulated by Hh signaling, and that a functional CXCR4 pathway was necessary to maintain a Hh-Gli1-NANOG network and self-renewal properties [125]. CXCR4/CXCL12 signaling also activates the Hh pathway in other cancer types, thus increasing tumor size, cell motility, angiogenesis, EMT, cell invasion, and NANOG expression [126]. Interestingly, there appears to be a mutual regulation of CXCR4 and NANOG in stem-like cancer cells, which could be mediated by PI3K/Akt/NF-κB and SHH/Gli1 pathways [126].

**CXCR7**

CXCR7 is a seven transmembrane-spanning chemokine receptor that, unlike typical GPCRs, is generally not coupled to Gαi proteins. It is an atypical chemokine receptor (ACKR3) that functions through G-protein-independent mechanisms in most cell types [127]. CXCR7 has multiple ligands, although the most widely studied is the chemokine CXCL12, which is also a ligand for CXCR4 [127]. The mechanisms of
signal transduction through this receptor are not fully known, but evidence suggests that in some cell types, CXCR7 forms heterodimers with CXCR4 to act as a co-receptor (Figure 2). CXCR7 can also signal via β-arrestin, which activates MAPK effectors [128]. Additionally, CXCR7 has been proposed to scavenge excess CXCL12 through high-affinity binding and degradation, which modulates ligand binding to CXCR4 [128].

Like CXCR4, CXCR7 can mediate various cancer processes, including tumor growth and metastasis. However, CXCR7 and CXCR4 appear to be co-expressed in some cancers (i.e. breast cancer lines like MDA-MB-231 and MCF-7 [129]), but not in others (recurrent glioblastoma [124]), suggesting that only MICs from select types of cancer utilize CXCR7 functions. In primary and recurrent glioblastoma patient samples, CXCR4 but not CXCR7 expression was correlated with the expression of pluripotency-associated genes [124]. In contrast, studies in other cancer types have reported that CXCR7 can regulate stemness and the expression of pluripotency transcription factors. In lung cancer, CXCR7 expression is upregulated by TGF-β1 signaling, and this promotes motility, invasion, EMT, and an increase in TIC features in cancer cells [130]. TGF-β1 signaling also upregulated other chemokine receptors, including CXCR4, although to a lesser extent. Upregulation of these chemokine receptors led to an increase in the transcript and protein levels of OCT4, SOX2, and NANOG, which was reversed by silencing CXCR4 and/or CXCR7. CXCL12 was also upregulated by TGF-β1 activation, and its binding to CXCR4 and/or CXCR7 was a crucial factor to promote expression of stemness genes. However, only CXCR7 was essential for EMT, and high expression of TGF-β1 and CXCR7 was correlated with poor patient survival. The authors proposed that TGF-β1-induced upregulation of CXCR7 occurs via the Smad pathway [130]. In breast cancer, CXCR7 is significantly overexpressed in CD44+/CD24low MICs. Furthermore, knocking down CXCR7 resulted in a significant loss of the CD44+/CD24low phenotype, along with decreased tumorsphere formation and reduced protein levels of OCT4 and NANOG. Silencing CXCR7 also inhibited tumor growth in a mouse xenograft model and sensitized cells to chemotherapy by increasing apoptosis [131]. Similarly, overexpressing the chemokine CXCL12 in a breast cancer cell line led to an upregulation of OCT4, SOX2, and NANOG, as well as an increase in stemness features and EMT markers [129]. CXCL12 treatment led to the nuclear translocation of p65 and increased IκB phosphorylation, suggesting an activation of the NF-κB pathway, and blocking this pathway impaired CXCL12-induced EMT [129].

**CX3CR1**

The chemokine receptor CX3CR1 is a seven transmembrane G-protein coupled receptor with a single known ligand, fractalkine (CX3CL1), and it is notably important for leukocyte adhesion and migration [132]. CX3CL1 can be expressed as a transmembrane protein that mediates cellular adhesion, and it can also be cleaved by metalloproteinases to produce a soluble protein that mediates chemotaxis [133-135] (Figure 3). Recently, numerous studies have implicated CX3CR1 in cancer progression. In ovarian cancer, CX3CR1 is generally overexpressed, and the degree of overexpression correlates with cancer stage [136]. Follow up studies in ovarian cancer cell lines showed that hypoxia upregulated CX3CR1, and these cells responded to CX3CL1 in cell spheroid invasion assays. In select lung cancer cell lines, CX3CR1 signals through the Src/FAK axis to promote both migration and invasion in transwell and Matrigel assays, and this was blocked by saracatinib, a small molecule inhibitor of Src family kinases [137]. In breast cancer, CX3CR1 expression correlates with brain metastasis [138], and CX3CR1 is also expressed within spinal metastases and acts through the Src/FAK signaling axis to promote migration and invasion [139]. When breast cancer cells are injected into the left ventricle of mice, CX3CR1 drives cancer cells to the skeleton through interactions with CX3CL1 expressed by bone marrow endothelial cells [140]. This skeletal seeding can be inhibited by a small-molecule antagonist of CX3CR1, which also impairs metastatic progression in the same model [141]. CX3CR1 is expressed on circulating tumor cells, and inhibiting this receptor keeps the cells in systemic circulation, which promotes apoptosis [142]. Prostate cancer spinal metastases express high levels of CX3CR1, and overexpression of CX3CR1 in prostate cancer cell lines promotes proliferation, migration, and invasion while inhibiting apoptosis [143]. Follow up studies in prostate cancer cell lines show that they express CX3CR1, the receptor enhances migration in a scratch wound assay, and migration is dampened by CX3CR1 knock-down or by inhibitors of the Src/FAK pathway. Like breast cancer cells, CX3CR1 expression by prostate cancer cells drives their adherence to bone marrow endothelial cells [144], and malignant transformation is associated with increased expression of CX3CR1 [145] (Figure 3).

Recently, we reported that human tissue specimens of prostate and breast tumors harbor cells that express high levels of CX3CR1 (CX3CR1<sup>high</sup>), and these CX3CR1<sup>high</sup> cells co-express OCT4 and NANOG...
Additionally, human prostate and breast cancer cell lines contain a sub-population of CX3CR1\textsuperscript{High} cells, with CX3CR1 expression consistently correlating with high OCT4 and NANOG expression in comparison to cells with low CX3CR1 expression (CX3CR1\textsuperscript{Low}) [146]. We further demonstrated that CX3CR1\textsuperscript{High} cells were enriched for stemness features using global transcriptome analysis [146]. When pure populations of CX3CR1\textsuperscript{High} or CX3CR1\textsuperscript{Low} cells were injected via the intracardiac route in an animal model of metastasis, the CX3CR1\textsuperscript{High} cells showed the highest propensity to initiate and develop metastatic lesions [146]. Furthermore, whole transcriptome analysis revealed that CX3CR1\textsuperscript{High} cells were de-enriched for the Hallmark apoptosis signature [146]. High CX3CR1 status resulted in resistance to docetaxel treatment, which is the standard-of-care chemotherapy for breast and prostate cancer [146]. The crucial findings of this study indicate that CX3CR1\textsuperscript{High} cells have a stemness phenotype that includes resistance to chemotherapy. Additionally, CX3CR1\textsuperscript{High} cells are endowed with metastasis-initiating ability in both prostate and breast cancer. We showed that lung cancer and melanoma cell lines also harbor CX3CR1\textsuperscript{High} sub-populations and have high levels of OCT4 and NANOG, indicating that CX3CR1 may be a pan-cancer marker of MICs [146].

**CCR subfamily**

**CCR4**

CCR4 is the receptor for two chemokine ligands: CCL17 and CCL22. This chemokine receptor is predominantly expressed by Th2 cells, cutaneous lymphocyte antigen-positive skin-homing T cells, and Treg cells. CCR4-expressing T cells are guided into inflamed skin by CCL17 and CCL22, and thus, the receptor regulates skin T cell homing and cutaneous inflammation [147].

CCR4 expression is also associated with tumor progression. High CCR4 expression in the tumor microenvironment corresponds with high levels of Tregs, which can generate an immunosuppressive microenvironment and facilitate the immune escape of malignant cells. In turn, overexpression of CCR4 has been associated with poor prognosis and decreased survival in different cancers [148,149]. Aberrant CCR4 expression in tumor cells has been associated with tumor progression and metastasis in breast cancer [150], hepatocellular carcinoma [151], and oral tongue cancer [152]. Recently, the expression of this receptor and its ligands were found to induce a TIC phenotype. Hepatocellular carcinoma cells express high levels of CCR4 [153], and treating these cells with either the conditioned medium from M2 macrophages, which express higher CCL17
levels than M1 macrophages, or with exogenous CCL17, promoted survival, migration, and tumorsphere formation. Furthermore, both treatments increased the relative levels of NANOG, OCT4, and SOX2 and enhanced Wnt/β-catenin activation [153]. The authors suggested that the Wnt/β-catenin pathway downstream of CCL17/CCR4 signaling regulated the stemness of hepatocellular carcinoma cells. Notably, coin-implantation of hepatocellular carcinoma cells with M2 macrophages significantly increased tumor growth in a mouse xenograft model compared to co-implantation with other types of cells, indicating that CCL17 can drive tumorigenicity [153].

**CCR7**

CCR7 is expressed by naïve lymphocytes, central memory T cells, and mature DCs. Its ligands, CCL19 and CCL21, are expressed by stromal cells within lymphoid organs, and are considered homeostatic chemokines as they direct cell recruitment under resting conditions [154]. This receptor/ligand axis plays an essential role in the migration of T cells towards lymphoid organs and DC homing to lymph nodes for antigen presentation [154].

CCR7 expression has been detected in breast cancer, non-small cell lung cancer, head and neck cancer, colorectal cancer, stomach cancer, melanoma, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and T cell leukemia [154]. Expression of this receptor has been associated with tumor aggressiveness, metastasis, and decreased patient survival [155]. Furthermore, multiple studies have implicated the overexpression of this receptor/ligand pair in the TIC phenotype. In pancreatic cancer, CCR7 expression was significantly increased in MICs as well as resected primary tumors and metastatic lymph nodes, and CCL21/CCR7 signaling promoted metastasis, EMT, and survival by modulating the ERK1/2/NF-κB pathway [156]. In colorectal cancer, CCR7 expression was associated with cancer progression, metastasis to the lymph nodes, and decreased patient survival [157,158]. *In vitro* studies of colorectal cancer cells showed that treatment with CCL21 upregulated P-glycoprotein and NANOG/OCT4, which enhanced chemotherapy resistance and promoted cell survival and tumorsphere formation, respectively [159]. The authors showed that the CCR7-mediated regulation of TIC features and pluripotency transcription factors required the EMT protein Snail, and that Snail was upregulated by CCL21 via PI3K/AKT/GSK-3β signaling [159]. Additionally, this receptor/ligand axis has been implicated in the regulation of stemness features in oral squamous cell carcinoma (OSCC) [160]. CCR7 and its ligand CCL21, but not CCL19, were overexpressed in diseased oral tissues from OSCC patients, and CCR7 expression correlated with a poor prognosis [160]. Studies in OSCC cell lines showed that exogenous CCL21 stimulation upregulated OCT4 and other TIC markers and enhanced EMT and stemness features, including migration, invasion, tumorsphere formation, and colony formation. CCL21 treatment increased the phosphorylation of JAK2 and STAT3, while treatment with a JAK2 inhibitor suppressed both CCL21-induced EMT and the TIC phenotype [160]. These results suggest that the CCL21/CCR7 axis regulates EMT and the stemness of OSCC cells through the activation of the JAK2/STAT3 pathway.

It is crucial to establish the master regulator transcription factors and signaling pathways that confer a TIC phenotype as a potential means of therapeutically targeting this small group of cells. The evidence that chemokine receptors can both identify and drive the TIC phenotype is a fundamental finding, as the surface expression of chemokine receptors can be used to isolate sub-populations of MICs. Chemokine receptors have been widely studied in immune cells, and there are good reagents and protocols available to study these receptors. By using FACS to isolate MICs based on the surface expression of chemokine receptors, pure sub-populations of MICs can be further characterized at the molecular level.

**Conclusions**

Together, the master regulator transcription factors OCT4, NANOG, and SOX2 form a core that establishes the pluripotent state in embryonic stem cells. This is achieved by increasing the expression of pluripotency factors, including themselves, and by repressing genes that encode lineage-specific factors [161]. Co-expression of these master regulator transcription factors has been found in a wide range of cancer types, especially in poorly differentiated tumors, where they control the fate of MICs during cancer progression [162]. In addition, several studies have demonstrated that increasing the expression of these pluripotency transcription factors in non-MICs leads them to acquire a TIC phenotype [162]. Given that OCT4, SOX2 and NANOG are crucial to maintain stemness, we need a greater knowledge of the mechanisms that regulate the expression of these factors to design new therapeutic interventions that can eventually overcome issues such as chemotherapy resistance, tumor recurrence, and metastasis. This review summarizes the various signaling pathways that activate these master regulator transcription factors, thus generating the TIC phenotype. With chemokine receptors upstream of these signaling pathways,
pathways and master regulator transcription factors, further studies are needed to characterize their role in tumor initiation and cancer cell stemness. This newly acquired knowledge will be paramount to pursue chemokine receptors as therapeutic targets.

**Abbreviations**

PI3K: phosphoinositide 3-kinase; AKT: alpha serine/threonine protein kinase; TGF-β: transforming growth factor beta; EGRF: epidermal growth factor receptor; JAK: janus kinase; STAT: signal transducer and activator of transcription; HER2: human epidermal growth factor 2; ER: estrogen receptor; EMT: epithelial mesenchymal transition; FOXC1: forkhead box C1; MAPK: mitogen-activated protein kinase; ERK: extracellular signal regulated kinase; CREB: cAMP response element binding protein; MEK: mitogen-activated kinase; FAK: focal adhesion kinase.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Al-Haji M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc National Acad Sci. 2003; 100: 3983–8.

2. Matfand NJ, Collins AT. Prostate Cancer Stem Cells: A New Target for Therapy. J Clin Oncol. 2008; 26: 2962–70.

3. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106–10.

4. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008; 451: 345–9.

5. Zhang S, Balch C, Chan MW, et al. Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. Cancer Res. 2008; 68: 61–20.

6. Cella-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Dev. Gev. 2016; 30: 892–908.

7. Gupta GP, Massagué J. Cancer Metastasis: Building a Framework. Cell. 2006; 124: 685–705.

8. Rodova M, Fu J, Watkins DN, Srivastava RK, Shankar S. Sonic Hedgehog Pathway for Cancer Drug Discovery. Nat Rev Drug Discov. 2005; 4: 988–1004.

9. Schaefer T, Wang H, Mir P, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget. 2015; 6: 43540–56.

10. Qin J, Ji J, Deng R, et al. DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by down-regulating Sox2. Oncotarget. 2015; 6: 6944–56.

11. Van Dijk J, Chen C, Lu Y, Mills GB. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discov. 2005; 4: 988–1004.

12. Schaefer T, Lengerke C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond. Oncogene. 2020; 39: 278–92.

13. Schaefer T, Wang H, Mir P, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget. 2015; 6: 43540–56.

14. Qin J, Ji J, Deng R, et al. DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by down-regulating Sox2. Oncotarget. 2015; 6: 6944–56.

15. Van Dijk J, Chen C, Lu Y, Mills GB. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discov. 2005; 4: 988–1004.

16. Schaefer T, Lengerke C. SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond. Oncogene. 2020; 39: 278–92.

17. Schaefer T, Wang H, Mir P, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget. 2015; 6: 43540–56.

18. Qin J, Ji J, Deng R, et al. DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by down-regulating Sox2. Oncotarget. 2015; 6: 6944–56.

19. Van Dijk J, Chen C, Lu Y, Mills GB. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nat Rev Drug Discov. 2005; 4: 988–1004.
Seo EJ, Kim DK, Jang IH, et al. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. 2016; 7: 35624-38.
113. Li H, Rong S, Chen C, et al. Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells. Mol Carcinogen. 2019; 58: 171-84.

114. Kundu N, Ma X, Box R, et al. The Chemokine Receptor CXCR3 Isomorph B Drives Breast Cancer Stem Cells. Breast Cancer Basic Clin Res. 2019; 13: 117823419873628.

115. Zhang Y, Zhao W, Li S, et al. CXCL11 promotes self-renewal and tumorigenicity in liver tumor-initiating cells through CXCR4/ERK1/2 signaling. Cancer Lett. 2019; 449: 163-74.

116. Jacobson O, Weiss ID. CXCR4 Chemokine Receptor Overview: Biology, Pathology and Applications in Imaging and Therapy. Theranostics. 2013; 3: 1-26.

117. Chatterjee S, Azad BB, Nimmagadda S. The Intricate Role of CXCR4 in Cancer. Adv Cancer Res. 2014; 124: 31-62.

118. Gassenmaier M, Chen D, Buchner A, et al. CXC Chemokine Receptor 4 is Essential for Maintenance of Renal cell Carcinoma-Initiating Cells and Predicts Metastasis. Stem Cells. 2013; 31: 1467-76.

119. Huang W-S, Hsieh M-C, Huang C-Y, et al. The Association of CXC Receptor 4 Mediated Signaling Pathway with Oxaliplatin-Resistant Human Colorectal Tumor Cells. Cell Death Dis. 2016; 7: e19927.

120. Wang X, Cao Y, Zhang S, et al. Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer. Oncotarget. 2017; 8: 36149-60.

121. Jung MJ, Rho JK, Kim Y-M, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013; 32: 209-211.

122. Gravina GL, Mancini A, Colapinto A, et al. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumor Biol. 2017; 39: 1010428317695528.

123. Lee C-C, Lai J-H, Hueng D-Y, et al. Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma. Cancer Cell Int. 2013; 13: 85-95.

124. Flüh C, Flatterman K, Meldrum HM, Synowitz M, Held-Feindt J. Differential expression of CXCR4 and CXCR7 with various stem cell markers in paired human primary and recurrent glioblastomas. Int J Oncol. 2016; 48: 1408-16.

125. Fareh M, Turchi L, Virolle V, et al. The disintegrin-like metalloproteinase ADAM17 mediates the cleavage and shedding of fractalkine analogues from the cell surface in breast cancer cells. Breast Cancer Res. 2011; 13: R91.

126. Jacobson O, Weiss ID. CXCR4 Chemokine Receptor Overview: Biology, Pathology and Applications in Imaging and Therapy. Theranostics. 2013; 3: 1-26.

127. Chatterjee S, Azad BB, Nimmagadda S. The Intricate Role of CXCR4 in Cancer. Adv Cancer Res. 2014; 124: 31-62.

128. Gassenmaier M, Chen D, Buchner A, et al. CXC Chemokine Receptor 4 is Essential for Maintenance of Renal cell Carcinoma-Initiating Cells and Predicts Metastasis. Stem Cells. 2013; 31: 1467-76.

129. Kong L, Guo S, Liu C, et al. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and breast cancer stem cell-like phenotypes of breast cancer cells. Int J Oncol. 2016; 48: 1085-94.

130. Wu Y-C, Tang S-J, Sun G-H, Sun K-H. CXCR7 mediates TGF-β1 inducible MET and tumor-initiating features in lung cancer. Oncogene. 2016; 35: 2123–60.

131. Shen F, Zhang Y, Jernigan DL, et al. Novel Small-Molecule CXCR1 Antagonist Impairs Seedling and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016; 14: 518-27.

132. Li J-Y, Ou Z-L, Yu S-J, et al. The chemokine receptor CXCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Res Tr. 2012; 131: 85-48.

133. Qian C, Worrede-Mahdi A, Shen F, et al. Impeding Circulating Tumor Cell Metastasis. Stem Cells. 2013; 31: 1467–76.

134. EnaNatala A, Kaur R, Qian C, et al. Subsets of cancer cells expressing CXCR4 are endowed with metastasis-initiating properties and resistance to chemotherapy. Oncogene. 2022; 1-15.

135. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015; 27: 11-20.

136. Jacobson O, Weiss ID. CXCR4 Chemokine Receptor Overview: Biology, Pathology and Applications in Imaging and Therapy. Theranostics. 2013; 3: 1-26.

137. Shulby SA, Doloff NG, Stearns ME, Meucci O, Fatatis A. CXCR1-Fractalkine Expression Regulates Cellular Mechanisms Involved in Adhesion, Migration, and Survival of Human Prostate Cancer Cells. Cancer Res. 2004; 64: 4695-8.

138. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts sites of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006; 17: 945–51.

139. Kong L, Guo S, Liu C, et al. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells. Int J Oncol. 2016; 48: 1085-94.

140. Liu P, Liang Y, Jiang L, Wang H, Wang S, Dong J. CXCL11/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway. Int J Oncol. 2018; 53: 1544-56.

141. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T Cells Recruited through CCL22/CXCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Res. 2009; 69: 2000–9.

142. Qian C, Worrede-Mahdi A, Shen F, et al. Impeding Circulating Tumor Cell Metastasis. Stem Cells. 2013; 31: 1467-76.